Literature DB >> 2263971

Prognosticating study for cervical myelopathy using evoked spinal cord potentials.

K Shinomiya1, A Okamoto, H Komori, T Matsuoka, H Yoshida, N Muto, K Furuya.   

Abstract

One hundred twenty-three cases of cervical spondylotic and ossification of the posterior longitudinal ligament (OPLL) myelopathy cases with long tract signs subjected to surgical treatment were studied to identify the most important factors having an influence on postoperative outcome using evoked spinal cord potentials (ESCP). Disappearance and positive wave changes of these potentials at the level of responsible lesions and slow conduction velocity under 40 m indicated an unsatisfactory outcome. Localized-lesion cases diagnosed by ESCPs had excellent results, significantly more so than extensive-lesion cases, regardless of operative methods. In 123 cases, 76% were found to have localized lesions, while the other 24% showed extensive lesions. Concerning the difference between CSM and OPLL, 54% of OPLL and only 14% of CSM demonstrated extensive lesions.

Entities:  

Mesh:

Year:  1990        PMID: 2263971     DOI: 10.1097/00007632-199015100-00013

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

1.  Application of time-frequency analysis to somatosensory evoked potential for intraoperative spinal cord monitoring.

Authors:  Y Hu; K D K Luk; W W Lu; J C Y Leong
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-01       Impact factor: 10.154

2.  Ossification of the posterior longitudinal ligament in three geographically and genetically different populations of ankylosing spondylitis and other spondyloarthropathies.

Authors:  C Ramos-Remus; A S Russell; A Gomez-Vargas; A Hernandez-Chavez; W P Maksymowych; J I Gamez-Nava; L Gonzalez-Lopez; A García-Hernández; E Meoño-Morales; R Burgos-Vargas; M E Suarez-Almazor
Journal:  Ann Rheum Dis       Date:  1998-07       Impact factor: 19.103

3.  Spinal cord evoked potentials in cervical and thoracic myelopathy.

Authors:  H Baba; N Kawahara; K Tomita; S Imura
Journal:  Int Orthop       Date:  1993       Impact factor: 3.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.